$Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults$

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults

<p>In this phase 4 study we assessed boosting with fractional doses of heterologous COVID-19 vaccines in Brazilian adults primed with two doses of CoronaVac (Sinovac/Butantan, São Paulo, Brazil) at least 4 months previously. Participants received either full-dose of ChAdOx1-S (Group...

Full description

Bibliographic Details
Main Authors:	Costa Clemens, SA, Marchevsky, N, Kelly, S, Felle, S, Eldawi, A, Rajasingam, R, Mahmud, R, Lambe, T, Voysey, M, Gonzalez, I, Milan, EP, Justino, MC, Bibi, S, Aley, P, Clemens, R, Pollard, AJ
Format:	Journal article
Language:	English
Published:	Taylor and Francis 2023

Similar Items

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
by: Sue Ann Costa Clemens, et al.
Published: (2023-08-01)

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
by: Chenchit Chayachinda, et al.
Published: (2023-08-01)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
by: Thuy Trang Nguyen, et al.
Published: (2022-03-01)

Immunogenicity and Reactogenicity of the Booster Dose of COVID-19 Vaccines and Related Factors: A Panel Study from the General Population in Serbia
by: Maja Stosic, et al.
Published: (2022-05-01)

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
by: Voysey, M, et al.
Published: (2021)

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
by: Costa Clemens, SA, et al.
Published: (2022)

Immunogenicity and reactogenicity of repeated intradermal mRNA COVID-19 vaccines administered as a second booster dose in a Thai geriatric population
by: Prasert Assantachai, et al.
Published: (2024-01-01)

Methods for predicting vaccine immunogenicity and reactogenicity
by: Patrícia Gonzalez-Dias, et al.
Published: (2020-02-01)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
by: Xiaolan Yong, et al.
Published: (2023-12-01)

Immunogenicity and Reactogenicity of DTPa-IPV/Hib Vaccine Co-administered With Hepatitis B Vaccine for Primary and Booster Vaccination of Taiwanese Infants
by: Pei-Lan Shao, et al.
Published: (2011-06-01)

Heterologous Covid-19 vaccines intervention effect on reactogenicity
by: Wajeha Najeeb, et al.
Published: (2023-12-01)

Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children: study protocol for an individual participant data meta-analysis of randomised controlled trials
by: Voysey, M, et al.
Published: (2016)

Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222
by: Shu-Hsing Cheng, et al.
Published: (2022-10-01)

Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine
by: Viravarn Luvira, et al.
Published: (2024-12-01)

Booster doses of an inactivated F genotype mumps vaccine enhance immunogenicity in mice
by: Seo Yeon Kim, et al.
Published: (2024-03-01)

Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis
by: Pei Li, et al.
Published: (2023-01-01)

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
by: Pace, D, et al.
Published: (2016)

Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial
by: Diggle, L, et al.
Published: (2006)

Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial.
by: Diggle, L, et al.
Published: (2006)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
by: A.N. Mironov, et al.
Published: (2010-01-01)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
by: A.N. Mironov, et al.
Published: (2010-07-01)

Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients
by: Jakub Wroński, et al.
Published: (2022-10-01)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
by: Shaw, RH, et al.
Published: (2021)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
by: Guy Cohen, et al.
Published: (2022-11-01)

Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study
by: Asmik Asatryan, et al.
Published: (2021-03-01)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
by: Flaxman, A, et al.
Published: (2021)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose
by: Snape, M, et al.
Published: (2013)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
by: Snape, MD, et al.
Published: (2013)

COMPARISON OF REACTOGENICITY AND IMMUNOGENICITY OF LIVE VACCINES AGAINST INFECTIOUS LARYNGOTRACHEITIS
by: S. A. Pokhvalny, et al.
Published: (2018-05-01)

Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
by: Jisun Lee, et al.
Published: (2023-07-01)

Assessment of Reactogenicity and Immunogenicity of the Quadrivalent Live Attenuated Influenza Vaccine
by: D. A. Lioznov, et al.
Published: (2018-06-01)

Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial
by: Ahmet Omma, et al.
Published: (2022-11-01)

Safety and immunogenicity of homologous versus heterologous boosters and COVID-19 vaccine hesitancy: Is there any link?
by: Yusra Mashkoor, et al.
Published: (2022-11-01)

Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3–9-month intervals following two-dose inactivated vaccine (CoronaVac)
by: Yuting Liao, et al.
Published: (2022-11-01)

Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years
by: Gili Joseph, et al.
Published: (2022-11-01)

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
by: Pace, D, et al.
Published: (2015)

Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations
by: Suvimol Niyomnaitham, et al.
Published: (2023-01-01)

Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
by: Shashidhar Jaggaiahgari, et al.
Published: (2022-12-01)

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine
by: Auchara Tangsathapornpong, et al.
Published: (2023-02-01)

ANTIBODY RESPONSE TO BOOSTER DOSES OF HEPATITIS B VACCINE IN MEDICAL STUDENTS VACCINATED IN INFANCY
by: R. Mohd Noh, et al.
Published: (2023-08-01)